KPTI News and Press, Karyopharm Therapeutics Inc. From 04/19/20

Deals and Financings Leo Pharma, a Denmark dermatology company, acquired global rights to a novel treatment for atopic dermatitis ((AD)) and allergic asthma in an agreement worth up to $570 million. FB825 is a first-in-class candidate that targets the CεmX domain of membrane-bound IgE...

Gainers: NLS   +38.7% .   BIG   +15.4% . GRIN   +16.6%.  KPTI   +14.1% . PLUS   +13.4% . More news on: Nautilus, Inc., Big Lots, Inc., Grindrod Shipping Holdings Ltd., Stocks on the move, , Read more ...

New COVID-19 initiatives/developments from healthcare companies include Bristol-Myers Squibb's (NYSE: BMY ) expansion  of its existing patient support program aimed at helping unemployed U.S. patients who have lost their health insurance coverage due to the pandemic. The company is off...

− Company to Initiate a Global Randomized Clinical Trial to Treat Patients with COVID-19 − − XPO1 Inhibitors have Previously Demonstrated Preclinical Activity Against Numerous Respiratory Viruses (Including SARS-CoV) and Associated Inflammation – &...

Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...

NEWTON, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 151,200 shares of Karyophar...

NEWTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief Commercial Officer. In this role, Mr. Demaree will lead Karyopharm’s commercial strategy ...

NEWTON, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 119,500 shar...

NEWTON, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ opti...

NEWTON, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of Richard Paulson to its Board of Directors. Mr. Paulson is currently Executive Vice President and Chief Executive Office...